NCT05857098

Brief Summary

The physiopathology of trigeminal-autonomic cephalalgia, and more particularly of cluster headache (CH) is still partially unknown. Three main structures are involved: the trigeminovascular system, the cephalic afferents of the autonomic nervous system, and centrally the hypothalamus. There are many clinical arguments in favor of the involvement of the hypothalamus in CH. In addition, several radiological studies have confirmed the involvement of the posterior hypothalamic region in cluster attacks. Thus, a positron emission tomography study showed hyperactivity of the posteroinferior nucleus of the ipsilateral hypothalamus. Voxel based MRI studies have shown a bilateral increase in the volume of the inferoposterior part of the homolateral hypothalamus. The involvement of the posterior hypothalamic region or more precisely the ventral tegmental area of the midbrain therefore seems acquired, although its real role as a generator or modulator of pain remains to be precised. Deep brain stimulation (dBS) is used in the management of chronic drug-resistant CH with an overall efficacy in 2/3 of patients. Nevertheless, its mechanism of action remains poorly understood, thus limiting the selection of patients and the optimization of care. The lack of clear neurophysiological criteria to identify the neuronal population to be targeted is a major source of uncertainty in the positioning of dBS electrodes and parameters adjustment. In order to improve the understanding and at the same time the results of this technique, obtaining in vivo electrophysiological data seems mandatory. Local fields potentials (LFP) have been recordered by in vivo by dBS in other diseases (Parkinson's disease, tremor…) and their analysis has brought new insigights in the characterization and understanding of these pathology. New generations of neurostimulator (Percept Medtronic) enables continuous recording of LFP in implanted patients. The goal of our study is the recording of LFP at the time of CH attacks via the BrainSenseTM system. This system included in the stimulator allows in vivo collection of LFP in the absence and presence of stimulation. The pathophysiological data recordered will then be correlated with the clinical benefit of the dBS ( nulber of attacks, duration, pain intensity…). As it is a feasibility study, only 5 patients will be included.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
5

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 5, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 12, 2023

Completed
19 days until next milestone

Study Start

First participant enrolled

May 31, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2025

Completed
Last Updated

May 12, 2023

Status Verified

April 1, 2023

Enrollment Period

2 years

First QC Date

April 5, 2023

Last Update Submit

May 10, 2023

Conditions

Keywords

HypothalamusLocal Fields Potentials

Outcome Measures

Primary Outcomes (1)

  • Change in Local field potentials

    Local field potentials amplitudes registered by the patient during a cluster attack

    Between 0 to 12 months

Secondary Outcomes (4)

  • Change in Efficacy of deep brain stimulation on attacks frequency

    Between 0 to 12 months

  • Change in Efficacy of deep brain stimulation on pain intensity

    Between 0 to 12 months

  • Change Efficacy of deep brain stimulation in attacks duration

    Between 0 to 12 months

  • Change in Efficacy of deep brain stimulation on treatment

    Between 0 to 12 months

Interventions

Continuous recording of Local Field potentials in patients implanted with Deep brain stimulation

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients suffering from refractry chronic cluster headache

You may qualify if:

  • Adult patients (age : 18-70 years-old) suffering from refractory chronic cluster headache
  • Patients eligible for a deep brain stimulation in the ventral tegmental area of the mesencephalon
  • Patients implanted with a deep brain stimulation system PerceptTM Medtronic®

You may not qualify if:

  • Secondary cluster headache
  • Patients implanted with another device of deep brain stimulation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assistance Publique Hopitaux de Marseille

Marseille, France

Location

MeSH Terms

Conditions

Cluster HeadacheTrigeminal Autonomic Cephalalgias

Condition Hierarchy (Ancestors)

Headache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Central Study Contacts

Anne BALOSSIER, MD

CONTACT

Emilie GARRIDO-PRADALIE

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 5, 2023

First Posted

May 12, 2023

Study Start

May 31, 2023

Primary Completion

June 1, 2025

Study Completion

June 1, 2025

Last Updated

May 12, 2023

Record last verified: 2023-04

Locations